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Letter to the Editor
“Indeterminate lupus anticoa-
gulant” as the third category
TO THE EDITOR: Laboratory testing for the detection of 
lupus anticoagulant (LAC) is important for the diagnosis 
of antiphospholipid syndromes and hypercoagulable states. 
LACs are heterogeneous circulating autoantibodies directed 
against epitopes found on negatively charged phospholipids 
and proteins associated with the cell membrane and inhibit 
phospholipid-dependent coagulation tests in vitro. Howev-
er, LAC is actually prothrombotic agents and cause thrombo-
sis in vivo; therefore, accurate diagnosis is critical for risk 
assessment and long-term patient management with anti-
coagulants.
To improve the diagnostic sensitivity of LAC testing, the 
International Society of Thrombosis and Haemostasis (ISTH) 
published testing guidelines in 1995 [1], and in 2009, it 
updated guidelines for LAC detection, patient selection, 
choice of tests, calculation of cut-off value, and inter-
pretation of results [2]. Although mixing studies are simple 
in principle, interpretation of their results poses a consid-
erable challenge. The 2009 ISTH guidelines recommended 
using the 99th percentile of the normal values as a cut-off 
for determining clotting time correction. When the concen-
trations of LAC are low, the clotting time after mixing 
can erroneously return to the normal range, and the results 
may be interpreted as negative. This shows that low concen-
trations of LAC cannot be detected when the 99th percentile 
of the normal values is used as a cut-off.
Therefore, it is necessary to adopt a more stratified diag-
nostic strategy for LAC, especially for the clotting- time 
based test, to reduce the possibility of a false-negative result 
when the concentration of LAC is low. In this context, 
separate, third strategy should be introduced for individuals 
with “indeterminate LAC”. The results can be classified 
as “indeterminate LAC” when the outcomes of both LAC 
screening and the confirmatory test are positive but that 
of the mixing test is weakly positive. By introducing 
“indeterminate LAC” as a separate category, we can focus 
on patients who are thought to have a low concentration 
of LAC.
Alkayed and Kottke-Marchant reported that indetermi-
nate LAC results were common, and that the clinical charac-
teristics of these individuals differed from those with neg-
ative results [3]. In our laboratory, we classify LAC test 
results into 3 different categories: positive, negative, and 
indeterminate. Our data also show that patients with 
“indeterminate LAC” have heterogeneous clinical character-
istics, from absence of clinical symptoms to evident 
deep-vein thrombosis, pulmonary thromboembolism, or re-
current fetal loss. If indeterminate LAC results are ignored, 
these thrombotic diseases may remain undiagnosed.
We think that adding this third category will prove to 
be a good strategy both practically and clinically. We comple-
tely agree with the opinion of Alkayed and Kottke-Marchant.
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